Desk›Healthcare› Orchid Pharma Ltd
Orchid Pharma Ltd
BSE 524372 · NSE ORCHPHARMA · ISIN INE191A01027 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹929.20
-4.38%
BSE close, 28 August 2026
₹4,712.82 cr
5.1 cr shares · Micro cap
₹1,419.03 cr
as published
121.0× · 3.71×
EPS ₹7.68 · BV ₹250.46
811.33 / 45.21
₹ cr, as filed
22
5 selected · 23%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -17.8% |
|---|---|
| Against 52-week low | +97.2% |
| Day change | -4.38% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹7.68 |
|---|---|
| Price / earnings | 120.99× |
| Price / book | 3.71× |
| Book value — derived, price ÷ P/B | ₹250.46 |
| Return on equity | 3.06% |
| Operating margin | 8.24% |
| Net margin | 3.92% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 3.07%
- ROE as published
- 3.06%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 304.17 | 11.94 | 1.99 | 8.24% | 3.92% |
| Mar-26 · Q | 237.61 | 30.60 | 6.03 | 18.03% | 12.88% |
| FY25-26 | 811.33 | 45.21 | 8.91 | 11.59% | 5.57% |
Quarter on quarter
- Revenue, quarter on quarter
- +28.0%
- Net profit, quarter on quarter
- -61.0%
- Operating margin, quarter on quarter
- -979 bps
Disclosure profile 22 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| Results | 1 |
| Selected sub-total | 5 |
| Procedural | |
| General | 4 |
| AGM / EGM | 2 |
| Analyst / Investor Meet | 2 |
| Board Meeting | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Compliance Certificate | 1 |
| Monitoring Agency | 1 |
| Other Update | 1 |
| Outcome | 1 |
| Trading Window | 1 |
| Procedural sub-total | 17 |
| Total | 22 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
22 filings · 5 selected · busiest 2026-08-14
Filing rhythm · the twelve most recent
2026-08-242026-10-09
SelectedProcedural
Filings
22 in the window · 9 earlier on record
-
9 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
29 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 33rd Annual General Meeting of Orchid Pharma Limited Held on 29th September 2026
AGM/EGM / AGM View filing →
-
28 September 2026 ·
Closure of Trading Window
Intimation of Trading Window closure for Quarter-II of Financial Year 2026-27, ending on September 30, 2026.
Insider Trading / SAST / Closure of Trading Window View filing →
-
23 September 2026 ·
Intimation Under Regulation 30- Trading Approval Of Equity Shares Issued And Allotted Under Scheme Of Amalgamation
Intimation under regulation 30- Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation
Company Update / General View filing →
-
22 September 2026 ·
Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement Regulations), 2015
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
Company Update / General View filing →
-
21 September 2026 ·
Investor Roadshow Scheduled To Be Held In Mumbai
Investor roadshow scheduled to be held in Mumbai
Company Update / General View filing →
-
8 September 2026 ·
Reg. 34 (1) Annual Report.
Annual Report of the Company for FY 2025-26.
Others / Reg. 34 (1) Annual Report View filing →
-
8 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for FY 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
7 September 2026 ·
Notice Of 33Rd Annual General Meeting Of Orchid Pharma Limited ('The Company') For The F.Y. 2025-26
Notice of 33rd Annual General Meeting of the Company
AGM/EGM / AGM View filing →
-
3 September 2026 ·
Change in Management
Appointment of cost auditor for FY 2026-27 and change in designation of director.
Company Update / Change in Management View filing →
-
3 September 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board meeting.
Others / Outcome without intimation View filing →
-
24 August 2026 ·
Earnings Call Transcript
Transcript of Analysts/Investors earning call held with public at large on August 21, 2026.
Company Update / Earnings Call Transcript View filing →
-
21 August 2026 ·
Analyst / Investor Meet - Outcome
Audio Recording of the Analyst/Investor Earning Call for Q-1 ended on June 30, 2026
Company Update / Analyst / Investor Meet View filing →
-
20 August 2026 ·
Investor Presentation
Investors Presentation-Quarter 1 of F.Y.2026-27, ended on June 30, 2026.
Company Update / Investor Presentation View filing →
-
17 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of schedule of Analysts/Investors Earning call for the Quarter-1 ended on June 30, 2026.
Company Update / Analyst / Investor Meet View filing →
-
14 August 2026 ·
Statement Of Deviation Or Variation For The Quarter Ended June 30, 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional Placement
Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.
Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →
-
14 August 2026 ·
Monitoring Agency Report
Monitoring Agency Report for Quarter-1 of F.Y. 2026-27 ended June 30, 2026.
Company Update / Monitoring Agency Report View filing →
-
14 August 2026 ·
Outcome Of Board Meeting Held For Considering And Approving Revised Audited Financial Results For The Year Ended March 31, 2026 Pursuant To Scheme Of Merger.
Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of Merger
Company Update / General View filing →
-
14 August 2026 ·
Financial Results For Quarter-1 Of F.Y. 2026-27 Ended June 30, 2026.
Financial Results for Quarter-1 of F.Y. 2026-27 ended on June 30, 2026.
Result / Financial Results View filing →
-
14 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board meeting inter alia for considering and approving Unaudited Financial Results for Quarter-1 of F.Y. 2026-27, ended on June 30, 2026.
Board Meeting / Outcome of Board Meeting View filing →
-
11 August 2026 ·
Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 14, 2026.
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Limited reviewed financial ....
Board Meeting / Board Meeting View filing →
-
28 July 2026 ·
Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 01, 2026
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting ....
Board Meeting / Board Meeting View filing →
RSS feed for Orchid Pharma Ltd · the 50 most recent filings